Results 151 to 160 of about 4,091 (198)

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors. [PDF]

J Clin Med Res
Patel J, Shah S, Reddy A, Prajapati D, Pandya A, Sawhney S.   +5 more
europepmc   +1 more source

Identification of prognostic biomarkers and development of a prediction model for prostate cancer. [PDF]

Front Immunol
Chen D, Chen W, Ye R, Li L, Miao F, Kong X, Ning W, Jia J, Chen Q, Wang P, Yin B.   +10 more
europepmc   +1 more source

Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV. [PDF]

J Clin Invest
Kolossváry M, Sereti I, Zanni MV, Fichtenbaum CJ, Aberg JA, Bloomfield GS, Malvestutto CD, Currier JS, Chu SM, Diggs MR, Lu AB, deFilippi C, Foldyna B, McCallum S, Sponseller CA, Lu MT, Douglas PS, Ribaudo HJ, Grinspoon SK.   +18 more
europepmc   +1 more source

Innovative Lipid-Lowering Strategies: RNA-Based, Small Molecule, and Protein-Based Therapies. [PDF]

Endocrinol Metab (Seoul)
Jang Y, Rhee EJ, Choi SH.
europepmc   +1 more source

Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial. [PDF]

Nat Med
Gaudet D, Gonciarz M, Shen X, Leohr JK, Beyer TP, Day JW, Mullins GR, Zhen EY, Hartley M, Larouche M, Konrad RJ, Benichou O, Ruotolo G.   +12 more
europepmc   +1 more source

The role of ANGPTL3 in controlling lipoprotein metabolism [PDF]

Endocrine, 2016
Angiopoietin-like protein 3 (ANGPTL3) is a secretory protein regulating plasma lipid levels via affecting lipoprotein lipase- and endothelial lipase-mediated hydrolysis of triglycerides and phospholipids. ANGPTL3-deficiency due to loss-of-function mutations in the ANGPTL3 gene causes familial combined hypobetalipoproteinemia (FHBL2, OMIM # 605019), a ...
Matti Jauhiainen
exaly   +6 more sources

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease [PDF]

New England Journal of Medicine, 2017
Loss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been associated with decreased plasma levels of triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. It is not known whether such variants or therapeutic antagonism of ANGPTL3 are associated with a reduced risk of ...
Frederick E Dewey, Viktoria Gusarova, Richard L Dunbar   +2 more
exaly   +7 more sources

How ANGPTL3 Inhibition Will Help Our Clinical Practice?

Current Atherosclerosis Reports, 2023
Purpose of review: This review aims to summarize the most recently published literature highlighting the potential of pharmacological inhibition of ANGPTL3 in treating patients suffering from dyslipidemias.
Simone Bini, Ilenia Minicocci, Alessia Di Costanzo   +2 more
exaly   +2 more sources

Angptl3 Deficiency Is Associated With Increased Insulin Sensitivity, Lipoprotein Lipase Activity, and Decreased Serum Free Fatty Acids

Arteriosclerosis, Thrombosis, and Vascular Biology, 2013
OBJECTIVE: Angiopoietin-like 3 (Angptl3) is a regulator of lipoprotein metabolism at least by inhibiting lipoprotein lipase activity. Loss-of-function mutations in ANGPTL3 cause familial combined hypolipidemia through an unknown mechanism. APPROACH AND
Marianna Maranghi, Daniel J Rader, Katariina Öörni   +2 more
exaly   +2 more sources